Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06740851
Active, not recruiting Observational

Predictive Model for 1-Year Pain and Function Outcomes After Thumb Joint Surgery in Osteoarthritic Patients

NCT06740851 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Michael Oyewale
Phase
Observational
Started
2022-02-08
Last updated
2024-12-20

Condition(s) studied

OsteoarthritisThumb ArthritisArthroplasty of the MCP Joint

Investigational drug(s) / intervention(s)

Touch® Trapeziometacarpal Joint Arthroplasty

Touch® Trapeziometacarpal Joint Arthroplasty: The intervention involves primary trapeziometacarpal joint (TMJ) arthroplasty using the Touch® prosthesis, a dual-mobility implant designed for the treatment of osteoarthritis in the thumb.

Study summary

This study aims to develop a predictive model to help doctors better understand expected outcomes one year after thumb joint surgery for osteoarthritis. By analyzing clinical and patient-reported data from individuals who underwent surgery with the Touch® implant, the study seeks to predict pain levels and hand function 1-year after surgery. This information can support shared decision-making, set realistic expectations, and improve personalized treatment planning.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who were treated with a primary TMJ arthroplasty using the Touch® prosthesis for TMJ OA in our single-center prospective registry. * Patients who had completed their 1-year follow-up questionnaire Exclusion Criteria: * Revision surgery, * Not treated for primary osteoarthritis (i.e., secondary osteoarthritis or rheumatoid arthritis or other), * Did not sign the consent form

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Schulthess Klinik Zurich Canton of Zurich

Other trials for the same condition

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System Active, not recruiting
AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study Active, not recruiting
The Effectiveness of Heat Treatment on Knee Pain in Patients With Osteoarthritis - an International, Multicenter Clinical Investigation Recruiting
G7 BiSpherical Acetabular Shell PMCF Study Active, not recruiting
Persona Partial Knee Clinical Outcomes Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06740851 on ClinicalTrials.gov ↗ ← All trials in Switzerland